| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6192799 | Journal of Thoracic Oncology | 2015 | 6 Pages |
Abstract
PTPRF may have value as a predictive marker to identify which patients can obtain the greatest benefit from erlotinib in the post-first-line setting. Further research is warranted to determine the potential value of this marker in clinical decision-making.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Denis MD, Fred R. MD, PhD, Frances A. MD, Walter PhD, Paul PhD, David S. PhD, Barbara PhD,